Wir verpflichten uns zur wissenschaftlichen Forschung

O’Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O’Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley E. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128(3):541-51. Cited by 1319 other research publications.

Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O’Mahony L, Kiely B, Shanahan F, Quigley EM. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101(7):1581-90. Cited by 723 other research publications.

Brenner DM, Chey WD. Bifidobacterium infantis 35624: A novel probiotic for the treatment of IBS. Rev Gastroenterol Disord. 2009;9(1):7-15. Review. 
Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol. 2009;104(4):1033-49. Cited by 278.

Konieczna P, Groeger D, Ziegler M, Frei, R, Ferstl R, Shanahan F, Quigley EM, Kiely B, Akdis CA, O’Mahony L. Bifidobacterium infantis 35624 administration induces Foxp3 T Regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells. Gut. 2012;61(3):354-66.

Mayer EA. Clinical practice. Irritable bowel syndrome.N Engl J Med. 2008 Apr 17;358(16):1692-9. Cited by 192.

Groeger D, O’Mahony L, Murphy EF, Bourke JF, Dinan TG, Kiely B, Shanahan F, Quigley EM. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes. 2013;4(4):325-39.

Allen AP, Hutch W, Borre YE, Kennedy PJ, Temko A, Boylan G, Murphy E, Cryan JF, Dinan TG, Clarke G. Bifidobacterium longum 1714 as a translational psychobiotic: modulation of stress, electrophysiology and neurocognition in healthy volunteers. Transl Psychiatry. 2016; 1;6(11):e939.

2016

Allen AP, Hutch W, Borre YE, Kennedy PJ, Temko A, Boylan G, Murphy E, Cryan JF, Dinan TG, Clarke G. Bifidobacterium longum 1714 as a translational psychobiotic: modulation of stress, electrophysiology and neurocognition in healthy volunteers. Transl Psychiatry. 2016; 1;6(11):e939.

Schiavi E, Gleinser M, Molloy E, Groeger D, Frei R, Ferstl R, Rodriguez-Perez N, Ziegler M, Grant R, Moriarty TF, Plattner S, Healy S, O’Connell Motherway M, Akdis CA, Roper J, Altmann F, van Sinderen D, O’Mahony L. The surface associated exopolysaccharide of Bifidobacterium longum 35624 plays an essential role in dampening host pro-inflammatory responses and in repressing local TH17 responses. Appl Environ Microbiol. 2016 Oct 7. pii: AEM.02238-16.

Hoy-Schulz YE, Jannat K, Roberts T, Zaidi SH, Unicomb L, Luby S, Parsonnet J. Safety and acceptability of Lactobacillus reuteri DSM 17938 and Bifidobacterium longum subspecies infantis 35624 in Bangladeshi infants: a phase I randomized clinical trial. BMC Complement Altern Med. 2016; 16:44.

Altmann F, Kosma P, O’Callaghan A, Leahy S, Bottacini F, Molloy E, Plattner S, Schiavi E, Gleinser M, Groeger D, Grant R, Rodriguez Perez N, Healy S, Svehla E, Windwarder M, Hofinger A, O’Connell Motherway M, Akdis CA, Xu J, Roper J, van Sinderen D, O’Mahony L. Genome Analysis and Characterisation of the Exopolysaccharide Produced by Bifidobacterium longum subsp. longum 35624™. PLoS One. 2016; 11(9):e0162983.

2014

Lomasney KW, Cryan JF, Hyland NP. Converging effects of a Bifidobacterium and Lactobacillus probiotic strain on mouse intestinal physiology. Am J Gastrointest Liver Physiol. 2014 Jul 15;307 (2):G241-7.

2013

Charbonneau D, Gibb RD, Quigley EM. Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. Gut Microbes. 2013; 4(3):201-211.
Groeger D, O’Mahony L, Murphy EF, Bourke JF, Dinan TG, Kiely B, Shanahan F, Quigley EM. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes. 2013;4(4):325-39.
Konieczna P, Ferstl R, Ziegler M, Frei R, Nehrbass D, Lauener RP, Akdis CA, O’Mahony L. Immunomodulation by Bifidobacterium infantis 35624 in the murine lamina propria requires retinoic acid-dependent and independent mechanisms. PLoS One. 2013;8(5): e62617.
Scully P, Macsharry J, O’Mahony D, Lyons A, O’Brien F, Murphy S, Shanahan F, O’Mahony L. Bifidobacterium infantis suppression of Peyer’s patch MIP-1α and MIP-1β secretion during Salmonella infection correlates with increased local CD4+CD25+ T cell numbers. Cell Immunol. 2013;281(2):134-140.

2012

Konieczna P, Akdis CA, Quigley EMM, Shanahan F, O’Mahony. Portrait of an immunoregulatory Bifidobacterium. Gut Microbes 2012;3(3): 261-266.
Konieczna P, Groeger D, Ziegler M, Frei, R, Ferstl R, Shanahan F, Quigley EM, Kiely B, Akdis CA, O’Mahony L. Bifidobacterium infantis 35624 administration induces Foxp3 T Regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells. Gut. 2012;61(3):354-66.
Quigley E, Catanzaro D, Wycherley C, Tillisch K. Tolerability and safety of the probiotic Bifidobacterium infantis 35624: review of clinical and postmarketing data. Am J Gastroenterol. 2010;105(Suppl 1):S480-S481. Abstract 1305.
Symonds EL, O’Mahony C, Lapthorne S, O’Mahony D, Mac Sharry J, O’Mahony L, Shanahan F. Bifidobacterium infantis 35624 protects against Salmonella-induced reductions in digestive enzyme activity in mice by attenuation of the host inflammatory response. Clin Transl Gastroenterol.2012;3:e15.

2011

Catanzaro D, Quigley E, Wycherley C, Tillisch K. Tolerability and safety of the probiotic Bifidobacterium infantis 35624: review of clinical and postmarketing data. Can J Gastroenterol. 2011;25(Suppl A);A-47.
Frech TM, Khanna D, Maranian P, Frech EJ, Sawitzke AD, Murtaugh MA. Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating/distension. Clin Exp Rheumatol. 2011;29(2 Suppl 65):S22-5.
Gad M, Ravn P, Søborg DA, Lund-Jensen K, Ouwehand AC, Jensen SS. Regulation of the IL-10/IL-12 axis in human dendritic cells with probiotic bacteria. FEMS Immunol Med Microbiol. 2011;63(1):93-107. 
Johnson AC, Greenwood-Van Meerveld B, McRorie J. Effects of Bifidobacterium infantis 35624 on Post-Inflammatory Visceral Hypersensitivity in the Rat. Dig Dis Sci. 2011;56(11):3179-86.
Quigley E, Groeger D, O’Mahony L, Bourke J, Scully P, Dinan T, Shanahan F, Kiely B. Oral administration of the probiotic Bifidobacterium infantis 35624 to humans induces immunoregulatory responses in vivo. Am J Gastroenterol. 2011;106(Suppl 2):S463-4. Abstract 1228.

2010

Desbonnet L, Garrett L, Clarke G, Kiely B, Cryan JF, Dinan TG. Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression. Neuroscience. 2010 170(4):1179-88.
McKernan DP, Fitzgerald P, Dinan TG, Cryan JF. The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat.Neurogastroenterol Motil. 2010;22(9):1029-35.

2009

Abeln S, McCarthy N. Probiotic benefits demonstrated in a clinical setting translate to meaningful benefits in the real world: post marketing experience with the probiotic strain Bifidobacterium infantis 35624. Am J Gastroentoerol 2009;104(Suppl 3):S496. Abstract 1327.
Brenner DM, Chey WD. Bifidobacterium infantis 35624: A novel probiotic for the treatment of IBS. Rev Gastroenterol Disord. 2009;9(1):7-15. Review.
Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol. 2009;104(4):1033-49
Davies JM, Sheil B, Shanahan F. Bacterial signalling overrides cytokine signalling and modifies dendritic cell differentiation. Immunology. 2009;128(1 Suppl)
Sibartie S, O’Hara AM, Ryan J, Fanning A, O’Mahony J, O’Neill S, Sheil B, O’Mahony L, Shanahan F. Modulation of pathogen-induced CCL20 secretion from HT-29 human intestinal epithelial cells by commensal bacteria. BMC Immunol. 2009;10:54.
Wall R, Ross RP, Shanahan F, O’Mahony L, Kiely B, Quigley E, Dinan TG, Fitzgerald G, Stanton C. Impact of administered Bifidobacterium on murine host fatty acid composition. Lipids. 2010;45(5):429-36.

2008

Desbonnet L, Garrett L, Clarke G, Bienenstock J, Dinan TG. The probiotic Bifidobacteria infantis: an assessment of potential antidepressant properties in the rat. Journal of Psychiatric Research. 2008;43(2):164-74.
Mayer EA. Clinical practice. Irritable bowel syndrome.N Engl J Med. 2008 Apr 17;358(16):1692-9.
O’Mahony C, Scully P, O’Mahony D, Murphy S, O’Brien F, Lyons A, Sherlock G, MacSharry J, Kiely B, Shanahan F, O’Mahony L. Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation. PLoS Pathog. 2008;4(8):e1000112.
van der Kleij H, O’Mahony C, Shanahan F, O’Mahony L, Bienenstock J. Protective effects of Lactobacillus reuteri and Bifidobacterium infantis in murine models for colitis do not involve the vagus nerve. Am J Physiol Regul Integr Comp Physiol. 2008;295(4):R1131-7.

2007

Sheil B, Shanahan F, O’Mahony L. Probiotic effects on inflammatory bowel disease. J Nutr. 2007;137(3 Suppl 2):819S-24S.
Shilling D, Coffey C, Smith M, Kavanagh E, Kirwan W, Redmond H, Shanahan F, O’Mahony L . Bacterial stimulation combined with heat shock protein targeting induces potent dendritic cell anti-tumor responses in a murine model. Gastroenterology. 2005;128:A178 (Abstract S1250)
Symonds EL, O’Mahony C, O’Mahony D, O’Mahony L, Shanahan F. Probiotic prevention of digestive enzyme damage in a mouse model of Salmonella.Gastroenterology. 2007;132(4 Suppl 2):A714-5.

2006

Charbonneau D, Poehner R, Donovan-Brand R, Xu J, Fawcett D. Development of strain-specific molecular method for the identification of Bifidobacteriainfantis 35624. Gastroenterology. 2006;130(4 Suppl 2):A314.
Gilman J, Cashman KD. The effect of probiotic bacteria on transepithelial calcium transport and calcium uptake in human intestinal-like Caco-2 cells.Curr Issues Intest Microbiol. 2006;7(1):1-5.
O’Hara AM, O’Regan P, Fanning A, O’Mahony C, MacSharry J, Lyons A, Bienenstock J, O’Mahony L, Shanahan F. Functional modulation of human intestinal epithelial cell responses by Bifidobacterium infantis and Lactobacillus salivarius. Immunology. 2006;118(2):202-15.
O’Mahony L, O’Callaghan L, McCarthy J, Shilling D, Scully P, Sibartie S, Kavanagh E, Kirwan WO, Redmond HP, Collins JK, Shanahan F. Differential cytokine response from dendritic cells to commensal and pathogenic bacteria in different lymphoid compartments in humans. Am J Physiol Gastrointest Liver Physiol. 2006;290(4):G839-45.
Quigley EM, Whorwell PJ, Shanahan F, Vansinderen D, Xu J, Altringer L, O’Mahony L, Guarner F, Progid Investigators. Safety and tolerability of the probiotic organism Bifidobacterium infantis 35624: Clinical experience and molecular basis. Gastroenterology. 2006;130(4 Suppl 2):A493.
Shanahan F, Guarner F, Von Wright A, Vilpponen-Salmela T, O’Donoghue D, Kiely B, Progid Investigators. A one year, randomised, double-blind,placebo controlled trial of a Lactobacillus or a Bidifobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology.2006;130( 4 Suppl 2):A44.
Sheil B, MacSharry J, O’Callaghan L, O’Riordan A, Waters A, Morgan J, Collins JK, O’Mahony L, Shanahan F. Consumption of theprobioticBifidobacterium infantis 35624 influences subsequent immune responses to in vitro challenge of isolated murine Peyer’s patch cells withbacterial stimuli. Gastroenterology. 2006;130(4 Suppl 2):A371.
Sheil B, MacSharry J, O’Callaghan L, O’Riordan A, Waters A, Morgan J, Collins JK, O’Mahony L, Shanahan F. Role of interleukin (IL-10) in probiotic-mediated immune modulation: an assessment in wild-type and IL-10 knock-out mice. Clin Exp Immunol. 2006;144(2):273-80.
Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O’Mahony L, Kiely B, Shanahan F, Quigley EM. Efficacy of an encapsulatedprobioticBifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101(7):1581-90.

2005

Bairead E, O’Mahony L, MacSharry J, Scully P, Fanning A, Kiely B, O’Mahony S, Shanahan F, Quigley E. Alterations in immunological gene expression from colonic biopsies of female IBS patients following probiotic consumption. Gastroenterology, 2005, 128 (44).
Chang K, Fangyi L, Hendrix S, Altringer L, Charbonneau D, Poehner R, Carryl O, Trowbridge M, O’Mahony L, Quigley E, Shanahan F S. Modulation of cytokine profiles in healthy and IBS subjects following supplementation with the unique probiotic strain, Bifidobacterium infantis 35624 . P&G Health Sciences Institute Publication 2005. Gastroenterology, 2005;128, (4 Suppl 2):A661
Charbonneau D, Baria M, Poehner R, Mccauley-Myers D, Eads C, Furnish C, Donovan-Brand R. Impact of Bifidobacterium infantis 35624 on fecal flora from healthy and IBS subjects in a chemostat model. Gastroenterology. 2005;128(4 Suppl 2):A660-61.
Charbonneau DL, Altringer LA, Carryl OR, Chen K-S, Kidd KJ, Darcy T, Fawcett DH, Trowbridge M M, Jang C, Luo F, Poehner RD, Meller ST. Fecal flora effects following oral supplementation with Bifidobacteria infantis 35624 in healthy and IBS subjects. Can J Gastroenterol. 2005;19(Suppl SB):R1097.
Chen K-S, Luo F, Hendrix SW, Altringer LA, Charbonneau DL, Poehner RD, Carryl OR, Trowbridge MM, O’Mahony L, Shanahan F, Quigley E, MellerST.. Oral administration with a unique probiotic strain, Bifidobacterium infantis 35624, to IBS subjects normalizes their systemic immunological imbalance in cytokine profile toward healthy subjects. Can J Gastroenterol. 2005;19(Suppl SB):R.1112.
O’Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O’Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley E. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128(3):541-51.
O’Mahony L, Sheil B, Murphy C, Duke K, Murphy S, Kiely B, Shanahan F. Bifidobacterial induced cytokine production in vitro as predictive biomarkersofin vivo performance in the lymphocyte transfer model of IBD. Gastroenterology. 2005;128(4 Suppl 2):A619.
Quigley EM, Whorwell PJ, Altringer L, Morel J, O’Mahony L, Shanahan F. Probiotic use results in normalization of bowel movement frequency in IBS. Results from a clinical trial with the novel probiotic Bifidobacteria infantis 35624. Am J of Gastroenterology, 2005;100( 9 Suppl S):S326
Quigley EM, Whorwell PJ, Altringer L, Morel J, O’Mahony L, Shanahan F. Who is the responder to probiotic therapy in IBS? Data from a controlled clinical trial with Bifidobacterium infantis 35624. Am J Gastroenterol. 2005;100(9 Suppl S):A325-326.
Sommerfield D, MacSharry J, O’Mahony D, O’Mahony L, Kiely B, Shanahan F, Quigley EM Effect of probiotic feeding on Salmonella translocation in a Mouse model. Gastroenterology. 2005;128:A120.(Abstract 770)

2004

O’Callaghan L, Sheil B, MacSharry J, Collins J, O’Mahony L, Shanahan F. Cytokine responses in different lymphoid compartments in IL-10/ko mice fedBifidobacterium infantis. Gastroenterology. 2004;126:A563 (Abstract W1075).
O’Mahony L, Shiel B, MacSharry, O’Callaghan L, Collins J, O’Sullivan G, Kiely B, Shanahan F. Mechanism of probiotic/commensal mediated protection against invasive Salmonella infection. Gastroenterology. 2004;126:A516 (Abstract T1809).

2003

MacConaill LE, Butler D, O’Connell-Motherway M, Fitzgerald GF, van Sinderen D. Identification of two-component regulatory systems in Bifidobacteriuminfantis by functional complementation and degenerate PCR approaches. Appl Environ Microbiol. 2003;69(7):4219-26.
McCarthy J, O’Mahony L, O’Callaghan L, Sheil B, Vaughan E, Fitzsimons N, Fitzgibbon J, O’Sullivan GC, Kiely B, Collins JK, Shanahan F. Double blind,placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut. 2003;52(7):975-80.
O’Callaghan L, O’Mahony L, McCarthy J, Kavanaugh E, Kirwan W, Redmond P, Shanahan F, Collins J. Differential cytokine response of cells derived from different lymphoid compartments to commensal and pathogenic bacteria. Gastroenterology. 2003;124:A339 (Abstract M1253).
O’Regan P, Powers A, MacSharry J, O’Sullivan G, Kiely B, Collins J, O’Mahony L, Shanahan F. Plasticity of epithelial cell cytokine responses to commensal and pathogenic species. Gastroenterology. 2003;124:A113 (Abstract 827).
Sommerfield D, O’Brien N, Kiely B, Collins J, Shanahan F, O’Mahony L, Quigley E. Influence of Bifidobacterium infantis feeding on secretagogue response and gut barrier function in rats recovering from colitis. Gastroenterology. 2003;124:A311 (Abstract M1113).

2002

O’Callaghan L, O’Mahony L, O’Mahony K, Kavanaugh E, Kirwan W, Collins J, Shanahan F. Human cytokine production by mesenteric lymph node cells in response to probiotic and pathogenic bacteria. Gastroenterology. 2002;122:A151 (Abstract S1040).
O’Mahony L, Kenneally P, O’Donoghue M, Kiely B, Shanahan F, Collins J. Multi-organism comparison of probiotic performance in a murine model ofSalmonella typhimurimum infection. Gastroenterology. 2002:122:T1337.
Sheil B, O’Mahony L, O’Callaghan L, Collins J, Shanahan F. Variability in human cytokine responses to different Lactobacilli and Bifidobacteria.Gastroenterology. 2002;122:A281 (Abstract M1161).
von Wright A, Vilpponen-Salmela T, Llopis MP, Collins K, Kiely B, Shanahan F, Dunne C. The survival and colonic adhesion of Bifidobacterium infantis in patients with ulcerative colitis. International Dairy Journal. 2002;12:197-200.

2001

O’Mahony L, Zong Z, Sharma S, Aranda R, O’Sullivan G, Collins JK, Shanahan F. Probiotic bacteria and pathogenic bacteria elicit differential cytokine responses from dendritic cells. Gastroenterology. 2001;120:A315 (Abstract 1625).
2000
O’Mahony L, Dunne C, Feeney M, O’Halloran S, Kiely B, O’Sullivan GC, Shanahan FL, Collin JK. Probiotic human Bifidobacteria selection of a new strain and evaluation in vitro and in vivo. Gastroenterology. 2000;118(4 Suppl):A774.

1999

Dunne C, Murphy L, Flynn S, O’Mahony L, O’Halloran S, Feeney M, Morrissey D, Thornton G, Fitzgerald G, Daly C, Kiely B, Quigley EM, O’Sullivan G, Shanahan F, Collins JK. Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. Antonie Van Leeuwenhoek. 1999; 76(1-4):279-92. Review.